Novartis AG (NYSE:NVS) Stock Position Raised by Cyndeo Wealth Partners LLC

Cyndeo Wealth Partners LLC grew its position in Novartis AG (NYSE:NVS) by 2.7% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 4,725 shares of the company’s stock after purchasing an additional 123 shares during the period. Cyndeo Wealth Partners LLC’s holdings in Novartis were worth $460,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Geneos Wealth Management Inc. lifted its stake in shares of Novartis by 3.6% in the 4th quarter. Geneos Wealth Management Inc. now owns 30,156 shares of the company’s stock worth $2,934,000 after acquiring an additional 1,058 shares during the period. apricus wealth LLC lifted its stake in shares of Novartis by 2.8% in the 4th quarter. apricus wealth LLC now owns 21,813 shares of the company’s stock worth $2,123,000 after acquiring an additional 600 shares during the period. DGS Capital Management LLC lifted its stake in shares of Novartis by 18.0% in the 4th quarter. DGS Capital Management LLC now owns 12,601 shares of the company’s stock worth $1,226,000 after acquiring an additional 1,918 shares during the period. Harel Insurance Investments & Financial Services Ltd. lifted its stake in shares of Novartis by 10.0% in the 4th quarter. Harel Insurance Investments & Financial Services Ltd. now owns 3,763 shares of the company’s stock worth $366,000 after acquiring an additional 343 shares during the period. Finally, Southland Equity Partners LLC lifted its stake in Novartis by 12.7% during the fourth quarter. Southland Equity Partners LLC now owns 3,380 shares of the company’s stock valued at $329,000 after purchasing an additional 381 shares during the last quarter. Institutional investors own 13.12% of the company’s stock.

Novartis Stock Performance

Shares of NVS opened at $99.93 on Friday. The company’s fifty day moving average is $100.09 and its 200-day moving average is $108.69. Novartis AG has a 12 month low of $92.35 and a 12 month high of $120.92. The firm has a market cap of $204.25 billion, a price-to-earnings ratio of 11.61, a price-to-earnings-growth ratio of 1.42 and a beta of 0.57. The company has a quick ratio of 0.90, a current ratio of 1.11 and a debt-to-equity ratio of 0.55.

Novartis (NYSE:NVS) last posted its earnings results on Tuesday, October 29th. The company reported $2.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.94 by $0.12. Novartis had a net margin of 35.96% and a return on equity of 34.80%. The business had revenue of $12.82 billion for the quarter, compared to analyst estimates of $12.62 billion. During the same period last year, the business posted $1.74 EPS. Equities analysts expect that Novartis AG will post 7.62 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts recently commented on NVS shares. HSBC lowered shares of Novartis from a “hold” rating to a “reduce” rating in a research note on Wednesday, December 4th. Erste Group Bank reissued a “hold” rating on shares of Novartis in a research note on Tuesday, November 19th. Finally, BMO Capital Markets increased their target price on shares of Novartis from $118.00 to $120.00 and gave the company a “market perform” rating in a research note on Wednesday, October 30th. Two equities research analysts have rated the stock with a sell rating and six have assigned a hold rating to the stock. According to data from MarketBeat, Novartis presently has an average rating of “Hold” and a consensus target price of $123.38.

Novartis Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.